利润表
SERES THERAPEUTICS, INC.
MCRB
业绩概览
点击表格中任意一行将其添加到图表
单位：百万美元
| 指标 | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY | Dec 31, 2020 2020 FY | Dec 31, 2019 2019 FY | Dec 31, 2018 2018 FY | Dec 31, 2017 2017 FY | Dec 31, 2016 2016 FY | Dec 31, 2015 2015 FY |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
营业收入
|
0.79 | - | 126.33 | 7.13 | 144.93 | 33.22 | 34.51 | 28.27 | 32.10 | 21.77 | 0.00 |
|
营业成本
|
- | - | - | - | - | - | - | - | - | - | - |
|
毛利润
|
0.79 | - | 126.33 | 7.13 | 144.93 | 33.22 | 34.51 | 28.27 | 32.10 | 21.77 | - |
|
营业费用
|
94.76 | 121.32 | 234.31 | 253.62 | 209.42 | 121.35 | 106.38 | 128.55 | 123.50 | 114.61 | 54.86 |
|
研发费用
|
49.06 | 64.60 | 145.86 | 172.92 | 141.89 | 90.57 | 80.14 | 95.96 | 89.46 | 81.99 | 38.10 |
|
销售、一般及行政费用
|
39.16 | 53.18 | 87.74 | 79.69 | 69.26 | 30.78 | 24.75 | 32.60 | 34.04 | 32.62 | 16.76 |
|
其他营业费用
|
- | - | - | - | - | - | - | - | - | - | - |
|
营业利润
|
-93.97 | -121.32 | -107.98 | -246.49 | -64.49 | -88.13 | -71.88 | -100.28 | -91.40 | -92.84 | -54.86 |
|
营业外收入
|
99.67 | -4.46 | -5.74 | -3.67 | -1.09 | -1.00 | 1.60 | 1.34 | 2.02 | 1.26 | 0.08 |
|
利息收入
|
2.23 | 3.97 | 7.30 | 3.06 | 2.87 | 0.95 | 1.03 | - | - | 2.23 | 0.64 |
|
利息支出
|
0.00 | 12.19 | 13.18 | 6.02 | 2.91 | 2.92 | 0.50 | - | - | - | 0.10 |
|
其他营业外收入/支出
|
16.76 | 6.29 | 0.13 | -0.71 | -1.05 | - | - | - | - | - | - |
|
税前利润
|
- | - | - | - | - | - | - | - | - | - | - |
|
所得税费用
|
- | - | - | - | - | - | - | - | - | - | - |
|
少数股东损益
|
- | - | - | - | - | - | - | - | - | - | - |
|
净利润
|
5.70 | 0.14 | -113.72 | -250.16 | -65.58 | -89.13 | -70.28 | -98.94 | -89.38 | -91.58 | -54.78 |
补充资料
每股数据、派生项目及其他——不属于利润表
除特别注明外，单位均为百万美元
| 指标 | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY | Dec 31, 2020 2020 FY | Dec 31, 2019 2019 FY | Dec 31, 2018 2018 FY | Dec 31, 2017 2017 FY | Dec 31, 2016 2016 FY | Dec 31, 2015 2015 FY |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
折旧与摊销
|
- | - | - | - | - | - | - | - | - | - | - |
|
EBITDA
|
-89.84 | -115.85 | -101.74 | -239.86 | -58.55 | -81.55 | -64.27 | -92.42 | -84.14 | -88.63 | -54.13 |
|
基本每股收益
|
0.64 | 0.00 | -0.89 | -2.31 | - | - | - | - | - | - | - |
|
稀释每股收益
|
0.64 | 0.00 | -0.89 | -2.31 | - | - | - | - | - | - | - |
|
加权平均股数
|
8.86 | 155.40 | 128.00 | 108.08 | - | - | - | - | - | - | - |
|
稀释加权平均股数
|
8.87 | 155.40 | 128.00 | 108.08 | - | - | - | - | - | - | - |
|
综合收益
|
5.70 | 0.14 | -113.71 | -250.11 | -65.59 | -89.17 | -70.28 | -98.80 | -89.38 | -91.76 | -54.75 |